Clicky

Personalis, Inc.(PSNL)

Description: Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves approximately 45 biopharmaceutical customers, including a range of pharmaceutical companies. The company was founded in 2011 and is headquartered in Menlo Park, California.


Keywords: Biotechnology Pharmaceutical Cancer Biopharmaceutical Life Sciences Biology Telemedicine Telehealth Genomics Molecular Diagnostics Medical Genetics Cancer Therapies Applied Genetics Biopsy Treating Cancer Analysis Services Cancer Therapy Data Analysis Services Biopharmaceutical Customers Oncogenomics

Home Page: www.personalis.com

PSNL Technical Analysis

1330 O’Brien Drive
Menlo Park, CA 94025
United States
Phone: 650 752 1300


Officers

Name Title
Mr. John Stephen West Co-Founder, CEO, Pres & Director
Mr. Aaron L. Tachibana Sr. VP & CFO
Dr. Richard Chen M.D., M.S., MS Sr. VP of R&D and Chief Medical Officer
Dr. Russ B. Altman M.D., Ph.D. Co-Founder and Member of Clinical & Scientific Advisory Board
Dr. Euan A. Ashley DPHIL, FRCP, M.D., Ph.D. Co-Founder and Member of Clinical & Scientific Advisory Board
Dr. Atul Butte Co-Founder and Member of Clinical & Scientific Advisory Board
Dr. Michael Snyder Ph.D. Co-Founder and Member of Clinical & Scientific Advisory Board
Ms. Carol J. Tillis VP of Fin. & Admin.
Mr. Stephen M. Moore J.D. VP, Gen. Counsel & Corp. Sec.
Mr. Michael J Fitzpatrick VP of Worldwide Sales

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.5121
Price-to-Sales TTM: 1.5322
IPO Date: 2019-06-20
Fiscal Year End: December
Full Time Employees: 325
Back to stocks